Healthcare / Pharmaceutical RetailersShanghai
$12.34
-0.18 (-1.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $2.1B · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.4B
P/E
23.7x
↑EV/EBITDA
5.0x
↓ROE
5.8%
↑Gross Margin
32.3%
↓Debt/Equity
0.70
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.3%
FCF CAGR
+12.9%
FCF margin
13.0%
FCF / Net income
7.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.24B · net income $381.8M · FCF $2.89B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.24B | $22.24B | $22.36B | $22.44B | $20.18B |
| Net Income | $381.8M | $381.8M | $519.1M | $929.0M | $785.0M |
| EBITDA | $2.32B | $2.32B | $2.57B | $2.93B | $2.63B |
| EPS | 0.50 | 0.50 | 0.68 | 1.23 | 1.05 |
| Gross Margin | 32.3% | 32.3% | 33.2% | 32.5% | 31.9% |
| Operating Margin | 5.1% | 5.1% | 5.4% | 6.9% | 7.1% |
| Net Margin | 1.7% | 1.7% | 2.3% | 4.1% | 3.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.70 | 0.70 | 0.88 | 0.75 | 0.84 |
| Current Ratio | 0.90 | 0.90 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.89B | $2.89B | $1.52B | $2.11B | $2.01B |
| Returns | |||||
| ROE | 5.8% | 5.8% | 7.9% | 13.9% | 12.0% |
| Valuation | |||||
| P/E | 23.73 | 23.73 | 22.34 | 19.86 | 31.29 |
| EV/EBITDA | 5.00 | 5.00 | 5.84 | 7.35 | 10.48 |
| P/B | 1.44 | 1.44 | 1.76 | 2.75 | 3.76 |
| Growth & Yield | |||||
| Revenue Growth | -0.5% | -0.5% | -0.4% | 11.2% | — |
| EPS Growth | -26.5% | -26.5% | -44.7% | 17.6% | — |
| Dividend Yield | 1.8% | 1.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
29.9%
EPS terminal req.
$1.09
Spread vs growth
-56.3%
5Y implied EPS CAGR
21.5%
EPS terminal req.
$1.32
Spread vs growth
-48.0%
10Y implied EPS CAGR
15.6%
EPS terminal req.
$2.13
Spread vs growth
-42.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.8%
Start / end P/E
28.1x → 24.7x
EPS bridge
0.68 → 0.50
Residual
+3.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.